目前乳腺癌辅助化疗应用最多的仍是蒽环类及紫杉类药物。
Nowaday, the chemotherapeutic drugs of anthracycline and taxane are used widely in breast cancer.
目的观察吉西他滨联合卡培他滨治疗蒽环类耐药性晚期乳腺癌的疗效与毒性反应。
Objective To observe the results of gemcitabine combined with capecitabine on anthracycline-resistant breast cancer.
对复发性乳腺癌患者，吉西他滨的疗效则明显优于蒽环类和紫杉类药物（P<0。01）。
Results In primary breast cancer, the antitumor effect of taxane is better than anthracycline and gemcitabine(P <0.01).
对复发性乳腺癌患者，吉西他滨的疗效则明显优于蒽环类和紫杉类药物（P<0。01）。
Results In primary breast cancer, the antitumor effect of taxane is better than anthracycline and gemcitabine(P <0.01).
应用推荐